Skip to main content
Start with Your Protocol

Generate your free Executive Summary.

Enter a ClinicalTrials.gov NCT identifier. In minutes you will have a complete Executive Summary: structured findings, an executive bottom line, the PTII™ composite, and the provenance chain that backs every conclusion.

The clearest way to evaluate the operating system is to put a study through it. No registration required to see the Summary.

or

Protocol upload runs under NDA today. Book a 1-hour paid strategy session and we'll run your protocol on the call and walk the Study Intelligence Report with your team.

Free from a ClinicalTrials.gov NCT
PDF + saved report when you want them
Continuous source attribution on every value
What you will receive

The Executive Summary you generate looks like this. Real PTII composite. Real executive bottom line. Real provenance attached to every value.

Executive Summary
NCT02******

Phase III Immunotherapy Plus Chemotherapy Study in Advanced Non-Small-Cell Lung Cancer

Sponsor
Global Oncology Sponsor
Phase
3
Enrollment
616
Executive Assessment
Prism Trial Intelligence Index™v1
Frontline Phase 3 oncology with combination immunotherapy plus chemotherapy
84/ 100
High Complexity
v1 basis
  • Protocol Complexity Index
  • Operational Burden Index
  • Eligibility Strictness Index
Enters in v2 (corpus required)
  • Amendment Risk Index
  • Enrollment Velocity Index
Contributing Sub-Indices
Protocol Complexity Index(PCI)
Available
87/ 100

Combination regimen, mandatory tumor biopsy, multi-arm randomization

Operational Burden Index(OBI)
Available
82/ 100

Visit cadence and procedure load above frontline oncology average

Eligibility Strictness Index(ESI)
Available
71/ 100

Recent diagnosis with no prior systemic therapy narrows screening pool

Executive Bottom Line
Operational burden is driven by combination dosing logistics and tumor tissue requirements during screening. Eligibility narrows the pool to recently diagnosed patients without prior systemic therapy, which constrains enrollment velocity at community sites.
Recommendation previewStudy Intelligence Report

Site network expansion recommended

Analysis of eligibility criteria against the current site network indicates the screening pool narrows sharply at community oncology sites. Adding academic and tertiary community sites is recommended to protect screening volume.

EvidenceFIND-*Recommendations, evidence citations, and clickable provenance are included in the Study Intelligence Report (Tier 2).
Generated
Date
Current generation date
Engine
Current platform version
Assessment
Current assessment model
Corpus Snapshot
Current corpus
Build
Current release

Demonstration generated by PrismCDM using publicly available ClinicalTrials.gov protocol information (NCT02******). This analysis was independently produced by PrismCDM and has not been reviewed or endorsed by the study sponsor.

See the full sample artifact